CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo

(2012) Kathrin Klein et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures andin silicomodeling

(2012) Dong Dong et al.   DRUG METABOLISM REVIEWS

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

(2012) Laure Elens et al.   Pharmacogenetics and Genomics

Validation of tacrolimus equation to predict troughs using genetic and clinical factors

(2012) Chaitali Passey et al.   PHARMACOGENOMICS

Dosing equation for tacrolimus using genetic variants and clinical factors

(2011) Chaitali Passey et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetic biomarkers: cytochrome P450 3A5

(2011) Iain A.M. MacPhee   CLINICA CHIMICA ACTA

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

(2011) L. Elens et al.   CLINICAL CHEMISTRY

Pharmacogenetics: From Bench to Byte— An Update of Guidelines

(2011) J J Swen et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Analysis of CYP3A4 genetic polymorphisms in Han Chinese

(2011) Qing Zhou et al.   JOURNAL OF HUMAN GENETICS

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

(2011) Laure Elens et al.   Pharmacogenetics and Genomics

Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients

(2011) Laure Elens et al.   PHARMACOGENOMICS

Genotypes and phenotypes of CYP3A in Bangladeshi population

(2010) Abdullah Al Maruf et al.   CLINICA CHIMICA ACTA

Effect of CYP3A and ABCB1 Single Nucleotide Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors: Part I

(2010) Christine E. Staatz et al.   CLINICAL PHARMACOKINETICS

Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis

(2010) Hui-Lin Tang et al.   Pharmacogenetics and Genomics

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

(2009) Yong Zeng et al.   ACTA PHARMACOLOGICA SINICA

Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference

(2009) Pierre Wallemacq et al.   THERAPEUTIC DRUG MONITORING

The CYP3A4*18 Genotype in the Cytochrome P450 3A4 Gene, a Rapid Metabolizer of Sex Steroids, Is Associated With Low Bone Mineral Density

(2008) YS Kang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans

(2008) P. J. Roberts et al.   DRUG METABOLISM AND DISPOSITION

Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone

(2008) M. Miyazaki et al.   DRUG METABOLISM AND DISPOSITION